



King's Research Portal

DOI: 10.1038/s41562-019-0738-8

Document Version Peer reviewed version

Link to publication record in King's Research Portal

Citation for published version (APA):

IMAGEN Consortium (2019). Identification of neurobehavioural symptom groups based on shared brain mechanisms. *Nature Human Behaviour*, *3*(12), 1306-1318. https://doi.org/10.1038/s41562-019-0738-8

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Identification of neurobehavioural symptom groups based on shared brain mechanisms

3 4 5

Authors: Alex Ing, Ph.D.¹; Philipp G. Sämann, M.D.², Ph.D.; Congying Chu, Ph.D.¹; Nicole 6 Tav. Ph.D.¹; Francesca Biondo, Ph.D.¹; Gabriel Robert, M.D.^{1,3}; Tianye Jia, Ph.D.¹; Thomas 7 Wolfers⁴; Sylvane Desrivières Ph.D.¹; Tobias Banaschewski M.D.; Ph.D.⁵; Arun L.W. Bokde 8 Ph.D.⁶; Uli Bromberg Ph.D.⁷; Christian Büchel M.D.^{7,8}; Patricia Conrod^{9,10}; Tahmine Fadai⁷; 9 Herta Flor Ph.D.^{11,12}; Vincent Frouin Ph.D.¹³; Hugh Garavan Ph.D.¹⁴; Philip A. Spechler, 10 M.A¹⁴; Penny Gowland Ph.D.¹⁵; Yvonne Grimmer⁵; Andreas Heinz M.D., Ph.D.¹⁶; Bernd 11 Ittermann Ph.D.¹⁷; Viola Kappel¹⁸; Jean-Luc Martinot M.D., Ph.D.¹⁹; Andreas Meyer-12 Lindenberg M.D., Ph.D.²⁰; Sabina Millenet Dipl.-Psych.⁵; Frauke Nees Ph.D.^{5,11}; Betteke van 13 Noort¹⁸; Dimitri Papadopoulos Orfanos Ph.D.¹³; Marie-Laure Paillère Martinot²¹; Jani 14 Penttilä²²; Luise Poustka M.D.²³; Erin Burke Quinlan Ph.D.¹; Michael N. Smolka M.D.²⁴; 15 Argyris Stringaris^{25,26}; Maren Struve²⁴; Ilya M. Veer Ph.D.¹⁶; Henrik Walter M.D., Ph.D¹⁶; 16 Robert Whelan Ph.D.²⁷; Ole A. Andreassen, M.D., Ph.D.^{28,29}; Ingrid Agartz, M.D., 17 Ph.D.^{29,30,31}; Hervé Lemaitre³²; Edward D. Barker^{33,1}; John Ashburner, Ph.D.³⁴, Elisabeth 18 Binder M.D.², Ph.D.; Jan Buitelaar M.D., Ph.D.⁴; Andre Marquand Ph.D.⁴; Trevor W. 19 Robbins, Ph.D.³⁵, Gunter Schumann M.D., Ph.D.^{1,36}*; IMAGEN Consortium. 20

21

- 22 Affiliations:
- ¹Centre for Population Neuroscience and Precision Medicine (PONS), Institute of
- Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, London,
 United Kingdom:
- ²Neuroimaging, Max Planck Institute of Psychiatry, Munich, Germany;

³ Behavior and Basal Ganglia research unit, University of Rennes, Rennes, France;

- ⁴ Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The
 Netherlands;
- ⁵ Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of
 Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;

- ⁶ Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience,
- 33 Trinity College Dublin, Dublin, Ireland;
- ⁷ Systems Neuroscience, University Medical Centre Hamburg-Eppendorf, Hamburg,
 Germany;
- ⁸ Department of Psychology, Stanford University, Stanford, California USA;
- ⁹ Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience,
 King's College London, UK;
- ¹⁰ Department of Psychiatry, Université de Montréal, CHU Ste Justine Hospital, Montreal
 QC, Canada;
- ¹¹ Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical
 Faculty Mannheim, Heidelberg University, Mannheim, Germany;
- 43 ¹² Department of Psychology, School of Social Sciences, University of Mannheim,
- 44 Mannheim, Germany;
- ¹³ NeuroSpin, CEA, Université Paris-Saclay, Gif-sur-Yvette, France;
- ¹⁴ Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont,
 USA;
- ¹⁵ Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of
 Nottingham, University Park, Nottingham, United Kingdom;
- ¹⁶ Department of Psychiatry and Psychotherapy CCM, Charité Universitätsmedizin Berlin,
- corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
 Institute of Health, Berlin, Germany;
- ¹⁷ Biomedical Magnetic Resonance, Physikalisch-Technische Bundesanstalt (PTB),
 Braunschweig and Berlin, Germany;
- ¹⁸ Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy,
 Charité, Humboldt University, Berlin, Germany;
- ¹⁹ Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000
- 58 "Neuroimaging & Psychiatry", University Paris Saclay, University Paris Descartes; DIgiteo-
- 59 Labs, Gif-sur-Yvette; and Maison de Solenn, Paris, France;
- ²⁰ Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical
 Faculty Mannheim, Heidelberg University, Mannheim, Germany;
- ⁶² ²¹ Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000
- 63 "Neuroimaging & Psychiatry", University Paris Saclay, University Paris Descartes; DIgiteo-
- 64 Labs, Gif-sur-Yvette; and AP-HP.Sorbonne Université, Department of Child and Adolescent
- 65 Psychiatry, Pitié-Salpêtrière Hospital, Paris, France;
- ²² Department of Social and Health Care, Psychosocial Services Adolescent Outpatient
 Clinic, Lahti, Finland;
- ²³ Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical
 Centre Göttingen, Göttingen, Germany;

- ²⁴ Department of Psychiatry and Neuroimaging Center, Technische Universität, Dresden,
 Dresden, Germany;
- ²⁵ Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology &
 Neuroscience, King's College London, London, United Kingdom;
- ²⁶ Mood Brain and Development Unit (MBDU), National Institute of Mental Health / NIH,
 Bethesda MD, USA;
- ²⁷ School of Psychology and Global Brain Health Institute, Trinity College Dublin, Dublin,
 Ireland;
- ²⁸ Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway;
- ²⁹ NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, Norway;
- ³⁰ Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway;
- ³¹ Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska
 Institutet, Stockholm, Sweden;
- ³² Institut National de la Santé et de la Recherche Médicale, UMR 992 INSERM, CEA,
- Faculté de médecine, Université Paris-Sud, Université Paris-Saclay, NeuroSpin, Gif-sur Yvette, France;
- ³³ Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's
 College London, London, United Kingdom;
- ³⁴ Wellcome Centre for Human Neuroimaging, UCL Institute of Neurology, University College
 London, London, United Kingdom;
- ³⁵ Department of Psychology and Behavioural and Clinical Neuroscience Institute, University
 of Cambridge, Cambridge, United Kingdom;
- ³⁶ PONS Research Group, Dept of Psychiatry and Psychotherapy, Campus Charite Mitte,
- 93 Humboldt University, Berlin and Leibniz Institute for Neurobiology, Magdeburg, Germany,
- and Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan
- 95 University, Shanghai, P.R. China.
- 96
- 97
- 98
- 99
- 100
- 101

102 Abstract:

Most psychopathological disorders develop in adolescence. The biological 103 basis for this development is poorly understood. To enhance diagnostic 104 105 characterisation, and develop improved targeted interventions, it is critical to 106 identify behavioural symptom groups that share neural substrates. We ran 107 analyses to find relations between behavioral symptoms, and neuroimaging 108 measures of brain structure and function in adolescence. We found two 109 symptom groups, consisting of anxiety/depression and executive dysfunction 110 symptoms respectively, which correlated with distinct sets of brain regions and inter-regional connections, measured by structural and functional 111 112 neuroimaging modalities. We found that the neural correlates of these symptom groups were present before behavioural symptoms had developed. 113 These neural correlates showed case-control differences in corresponding 114 psychiatric disorders, depression and ADHD, in independent clinical samples. 115 By characterising behavioral symptom groups based on shared neural 116 117 mechanisms, our results provide a framework for developing a classification 118 svstem for psychiatric illness, which is based on quantitative neurobehavioural measures. 119

120

121

122

123

124

125 Adolescence and its transition toward young adulthood is a critical period for the development of psychiatric illness with half of the lifetime psychopathological 126 burden emerging by the mid-teens, and 75% by the mid-20s¹. It coincides with major 127 structural changes in grey and white matter² that are particularly pronounced in the 128 limbic system and the prefrontal cortex³. Cognitive and (other) behavioural 129 maturation reflects this brain-wide developmental process⁴. As psychopathological 130 131 symptoms during adolescent brain re-organization are often unspecific, and in many cases reversible, it has been difficult to unambiguously identify early markers for 132 133 sustained mental illness. Thus, most patients present during adulthood, often at a 134 point when severe psychopathology has developed, which gravely impairs their daily functioning. Presentation at this advanced stage increases individual suffering and 135 136 renders therapeutic interventions more difficult.

137 Currently, both adolescent and adult psychiatric diagnoses are made on the basis of combinations of behavioural symptoms that - whilst reflecting the 138 139 psychopathological experience of generations of clinicians and patients - are not 140 necessarily related to homogeneous pathophysiological or etiological processes. This results in biological heterogeneity within diagnostic entities⁵, high rates of 141 comorbidity between diagnoses^{6,7}, and ill-defined targets for drug development. This 142 143 is particularly relevant in adolescence, where there is evidence to suggest that psychiatric illness is more dimensional and less categorical than adult 144 psychopathology. Neuroimaging methods offer the opportunity to identify the 145 biological mechanisms underpinning mental illness, without recourse to these 146 categorisations^{8,9}. 147

148 One of the challenges in breaking up diagnostic borders in favour of more 149 homogenous clusters of symptoms sharing common neural mechanisms, is that

150 biological and behavioral data need to be combined in a meaningful way. A suitable 151 method for this purpose is canonical correlation analysis (CCA), which is formulated 152 to maximize the correlation between variables in two views of a dataset. This 153 technique has previously been used to link complex behavioural datasets with functional brain networks¹⁰. However, CCA has a number of limitations: It cannot be 154 155 applied to data with more features than samples, results are difficult to interpret 156 owing to a lack of localizability, and it is only possible to find relations between two sets of variables. The first two of these issues can be addressed using sparse 157 canonical correlation analysis (sCCA)^{11,12}, which has been used to find modes of 158 159 shared variation between resting state functional connectivity MRI, and behavioral measures in adolescents and young adults¹². However, this approach is still limited 160 161 in that it is only possible to identify relations between psychiatric symptoms and one 162 kind of biological measure at a time. We further enhanced sCCA by formulating a 163 constrained form of multiple canonical correlation analysis, which maximizes the correlation between psychiatric symptoms, and several different neuroimaging 164 modalities simultaneously¹³, before combining them in a linear regression model; we 165 166 term this approach sparse multiple canonical correlation analysis regression 167 (msCCA-regression).

We investigated whether symptoms contributing to DSMV/ICD10 diagnoses can be reconfigured to identify 'neurobehavioral' symptom groups that best represent specific underlying dysfunctional brain networks in adolescence. Here, we used a data driven approach applied to a large general population neuroimaging sample to investigate direct relations between neuroimaging measures of brain structure and function, yet without immediate recourse to diagnostic psychiatric categories. Following this, we sought to determine whether the regions we found to be related to

psychiatric symptoms in adolescence were associated with fully-blown clinical psychopathology in several independent clinical samples. Overall, this multi-step approach enabled us to identify brain correlates of psychopathology in adolescence, probe their predictive value in the critical period between age 14 and age 19, and characterize these brain correlates against the development of full-blown psychopathology.

- 181
- 182

183 **Results**

We used msCCA-regression (please see the methods section under the sub-184 185 heading: Multiple Sparse Canonical Correlation Analysis Regression) to link 186 participant responses to the Development and Well Being Assessment (DAWBA), a structured interview for psychiatric DSMV/ICD-10 diagnoses¹⁴ (Supplementary Table 187 1), with voxel-based morphometry (VBM)¹⁵ measures of grey matter volume, 188 189 fractional anisotropy (FA) along major white matter tracts using tract-based spatial statistics (TBSS)¹⁶, and functional connectivity between different brain regions, 190 mapped from resting state (rs-fMRI) scans¹⁷. T₁ and DTI data were pre-processed 191 using voxel-wise VBM¹⁸ and TBSS¹⁹ methods respectively, as these procedures 192 193 have been extensively studied and applied to real data. We mapped inter-regional rs-fcMRI connections across the brain using nodal maps defined by Miller et al¹⁷. 194 195 reasons for our pre-processing and analysis choices are detailed in the methods 196 section of the paper under the sub-heading: Different Neuroimaging Pre-processing 197 Strategies. We investigated ninety DAWBA items (symptoms) related to a broad range of psychiatric disorders, including affective and anxiety symptoms, attention 198 199 deficit/hyperactivity and conduct symptoms, as well as substance use, eating

disorders, and symptoms of psychosis (Supplementary Table 1)¹⁴. This analysis was carried out on the general population IMAGEN sample, on participants of age 19. Following an in-depth QC (see methods under the sub-heading: IMAGEN analysis), data for n = 666 participants was available at age 19.

204 To avoid overestimating the variance shared between psychiatric symptoms, 205 and the neuroimaging modalities analysed (overfitting), we used a train/test analysis 206 design, which allows us to estimate effect sizes in an unbiased way. Using a test set 207 also allowed us to carry out further characterization of the data, without running into 208 circularity problems. We carried out model selection in a training dataset of 70% of 209 the data (n=467), and model validation in the testing dataset of the remaining 30% 210 (n=199). To enhance stability we resampled the data and retained only variables that 211 contributed to the model in 90% of resamples (see methods under the sub-heading: Stability Selection, and Supplementary Figure 1)²¹. Demographic information on the 212 full sample, training and testing sets is given in Supplementary Figure 2. The 213 214 msCCA-regression procedure we used in this investigation is designed to maximise associations between variable-sets. For this reason, all msCCA-regression 215 216 significance values reported in the text are one-sided.

217

Using msCCA-regression, we found a significant relation between a subset of six DAWBA symptoms (see Figure 1), and VBM, TBSS and rs-fMRI measures (r=0.59(465), p<0.001). The behavioural correlates derived from DAWBA covered symptoms linked to feelings of depression, anxiety and somatic problems, as well as temper and attentional problems (Figure 1). The model was also significant when applied to the test dataset (r=0.23(197), p<0.001, 95% Cls=0.13, ∞) (Figure 1), explaining 5.30% of the variance between psychiatric symptoms and the brain. Brain

correlates derived from VBM, TBSS and rs-fcMRI measures were associated with this anxiety/depression symptom group with correlation values of: r=0.16(197), p=0.017, 95% CIs=0.040, ∞ ; r =0.14(197), p=0.040, 95% CIs=0.037, ∞ and r=0.15(197), p=0.029, 95% CIs=0.041, ∞ respectively (with all p-values FWEcorrected for multiple comparisons, see methods under the sub-heading: Analysis Design, and Supplementary Figure 3).

VBM, TBSS and rs-fcMRI modalities all showed an individually significant 231 232 relation to psychopathology. We carried out further localization analyses in each 233 modality to identify brain regions that showed an individually significant relation to psychopathology (see methods under the sub-heading: Additional Analyses to 234 235 Localise Effects). In this localization analysis, we identified one gray matter cluster in the right inferior temporal gyrus (r=0.16(197), p=0.032 FWE corrected, 95% 236 237 Cls=0.041, ∞), and a single cluster of decreased fractional anisotropy in the genu of 238 the corpus callosum (r = 0.16(197), p=0.031 FWE corrected, 95% CIs=0.041, ∞). 239 Both of these brain regions have been among those exhibiting the largest differences 240 between healthy controls and patients with depression, in recent large, well-powered meta-analyses^{22,23}. Further, we found an increase in functional connectivity between 241 the default mode network, and the cerebellum (r=0.15(197), p=0.041 FWE corrected, 242 243 95% CIs=0.037, ∞); the default mode network has been implicated in several 244 different psychiatric disorders, but depression in particular, with recent research showing that connectivity between the cerebellum and the default mode network is 245 altered in patients with depression²⁴. Information on the full set of regions found to be 246 associated with psychiatric symptoms can be found in Supplementary Tables 2 and 247 248 3 and Supplementary Figures 4 and 5.

249 We then removed the effects of the first canonical relation and investigated 250 the presence of a second dimension of shared variance between symptoms and the 251 brain (see methods under the sub-heading: Finding Multiple Modes of 252 Variation). Here, we identified another behavioral correlate consisting of five items 253 from the DAWBA, including: problems with attention, fidgeting, rapidly changing 254 moods and (lack of) conscientiousness that was significantly associated with the 255 neuroimaging modalities (r=0.46(465), p=0.004). The test sample correlation is significant at (r=0.19(197), p=0.002, 95% CIs=0.087, ∞), explaining 3.61% of the 256 257 variance between psychiatric symptoms and the brain. Brain correlates derived from VBM, TBSS and rs-fcMRI measures were associated with the executive dysfunction 258 symptom group with correlation values of r=0.19(197), p=0.012, 95% CIs=0.079, ∞ ; 259 260 r=0.070(197), p=0.21, 95% CIs=-0.029, ∞ and r=0.020(197), p=0.58, 95% CIs=- $0.090, \infty$ respectively. These results are displayed in Figure 2. 261

262

As the VBM modality was the only modality in this second canonical relation 263 264 to show an individually significant relation to psychopathology, we only carried out a 265 localization analysis for VBM data in this modality; we found that executive 266 dysfunction symptoms correlated with a single grey matter cluster in the right middle temporal gyrus (r = 0.16(197), p = 0.024 FWE corrected, 95% CIs=0.049), an area 267 that has previously been shown to be associated with ADHD symptomology²⁵. 268 269 Information on the full set of regions found to be associated with psychiatric 270 symptoms can be found in Supplementary Tables 4 and 5 and Supplementary 271 Figures 4 and 5. Associations between canonical anxiety/depression and executive 272 dysfunction canonical correlates are given in Supplementary Table 6. Our results 273 were robust to different rs-fcMRI atlas choices, as shown by repeated analyses using

a different nodal definition²⁰, which generated similar results (Supplementary Figure
6).

276

277

278 Hypothesis Driven Analysis

279 To determine if the canonical symptom groups identified in our data-driven analysis show a stronger relation to neuroimaging measures than existing means of 280 281 organizing psychiatric symptoms, we carried out a hypothesis driven analysis using 282 internalizing and externalizing symptoms, which are often used in adolescent 283 psychiatric diagnostics. We tested whether the canonical symptom groups identified with msCCA-regression were able to explain more variance than this widely used 284 285 model of illness (see methods under the sub heading: Hypothesis Driven Analysis)²⁶. 286 We term these pre-defined symptom groups as DAWBA-internalising and DAWBA-287 externalising. We found that the correlation of the DAWBA-internalising dimension of 288 psychopathology with neuroimaging measures only shows trend-level significance in 289 the test set (r=0.12(197), p=0.060, 95% CIs=-0.02, ∞) and explains 1.9% of variance. 290 Similarly, DAWBA-externalising dimensions of psychiatric illness correlated with 291 neuroimaging measures at (r=0.040(197), p=0.28, 95% CIs=-0.095, ∞) in the test 292 set, explaining 0.16% of the variance (Supplementary Figure 7). We then used a modified version of Dunn and Clarke's $z^{27,28}$ to test directly whether the association 293 294 of the canonical symptom groups with the brain was significantly stronger than their pre-defined analogues. While the symptom-brain correlation of the executive-295 296 dysfunction symptom group was indeed significantly stronger than that of the 297 DAWBA-externalizing symptom group (Z=1.95(196), p = 0.029), we did not find 298 evidence that the strength of the association between the anxiety/depression symptom group and the brain was significantly larger than that of the DAWBAinternalizing group (Z=0.92(196), p = 0.18).

301

302 Longitudinal Analysis

303 We carried out the initial cross-sectional analysis relating psychiatric symptoms to 304 brain at age 19, as most psychopathological symptoms will have become manifest 305 by this age. To investigate how adolescent brain development relates to the 306 development of psychopathological symptoms, we analyzed data from the same 307 participants at age 14 years. First, we repeated the cross-sectional msCCA-308 regression analysis using VBM and TBSS (rsfMRI data was not available at age 14). We found a non-significant, trend level association between symptoms and 309 310 neuroimaging measures of r = 0.42(410), p = 0.11 in the training set. We found 311 similarly non-significant results in the testing set (r = 0.10(180), p = 0.090, 95% CIs=-312 $0.017,\infty$). The results of these analyses are displayed in Supplementary Figure 8.

313 There is previous evidence to suggest that neuroimaging measures precede the development of psychiatric symptoms in adolescence²⁹. We tested whether that was 314 315 the case with the canonical symptom groups established in the present study by 316 extracting the TBSS and VBM regions discovered at age 19 and using them as regions of interest at age 14. In order to obtain unbiased estimates of effect, we 317 318 looked for associations in the test sample. After a conservative quality control 319 procedure (see methods under the sub-headings: Longitudinal Analysis), n = 182 320 participants were available for analysis at this time-point. Our data did not show any 321 evidence of an association between anxiety/depression brain correlates and 322 anxiety/depression symptoms at 14 years r=0.020(180), p=0.40, 95% CIs=-0.10, ∞ . 323 However, the brain correlates taken from data at age 14, were predictive of

324	symptoms at age 19 r=0.14(180), p=0.023, 95% CIs=0.022, ∞ . These results are
325	shown in figure 3. The difference in correlation between brain correlates at age 14
326	years with anxiety/depression symptoms at 14 years and 19 years was also
327	significant, testing for a difference in association using a modified version of Dunn
328	and Clarke's Z (Z=1.74(179), p=0.041) ²⁸ . We did not find evidence of an association
329	between brain correlates and symptoms of executive dysfunction at age 14 years
330	(r=0.030(180), p=0.41, 95% CIs=-0.093, ∞). Prediction of symptoms at 19 years
331	showed a trend towards significance (r=0.11(180), p=0.065, 95% CIs =-0.010, ∞).

332

333

334

335

336 Clinical Characterization

337 We investigated whether the canonical correlates of psychopathology we identified in 338 a general population adolescent sample are correlated with fully developed 339 psychiatric illnesses. In these analyses, we looked for case-control differences in the 340 anxiety/depression and executive dysfunction canonical correlates, across four 341 common psychiatric illnesses in several independent clinical samples. We carried out 342 these analyses using VBM data alone, as this was the only data modality that 343 showed an individually significant association with both symptom groups. Clinical 344 and demographic information associated with the different clinical samples is 345 displayed in Supplementary Figure 9 and Supplementary tables 7-9. Extensive information on quality control and data exclusion criteria for these clinical samples is 346 347 given in the methods section of this paper following the sub-heading: Clinical

Analyses. In assessing this data, we were looking for a directional effect, we therefore report significance levels resulting from one-tailed tests in this section of the paper.

351 When analyzing the data for case-control differences in grey matter correlates of anxiety/depression symptoms, we found significant reductions in regional grey 352 353 matter volume in independent samples of patients with Depression (t-354 statistic=4.61(612), p<0.001, Cohen's D = 0.39, 95% CIs=0.25, ∞), Schizophrenia (tstatistic=2.54(445), p=0.002, Cohen's D=0.25, 95% CIs = 0.087, ∞) and in ADHD (t-355 356 statistic=1.84(203), p=0.034, Cohen's D=0.26, 95% CIs=0.030, ∞). In the executive 357 dysfunction grey matter correlates, we found significant differences between patients and healthy controls in ADHD (t-statistic=2.19(203), p=0.014, Cohen's D=0.32, 95% 358 359 Cls=0.070, ∞), Schizophrenia (t-statistic=2.84(445), p=0.0026, Cohen's D=0.28, 95% 360 Cls=0.11, ∞) and Depression (t-statistic=1.65(612), p=0.050, Cohen's D=0.14, 95% 361 Cls=0.001, ∞). We did not find significant effects of bipolar disorder along either of 362 these dimensions (t-statistic=-0.23(473), p=0.59, Cohen's D=-0.02, 95% CIs=-0.17, ∞) and (t-statistic=-1.33(473), p=0.90, Cohen's D=-0.12, 95% Cls=-0.27, ∞) 363 364 respectively (Figure 4). In these case-control analyses, the data distribution was 365 assumed to be normal but this was not formally tested. To test whether the observed reduction in grey matter was specific to the brain correlates identified, as opposed to 366 367 being a proxy for a generalized, brain-wide reduction in grey matter, we repeated the 368 clinical comparisons using total grey matter as a covariate of no interest in addition 369 to total intracranial volume (Supplementary Figure 10). ADHD and Depression 370 results were unaffected by this change in pre-processing. In contrast, the 371 Schizophrenia results were no longer significant.

372 373

374

375 Discussion

We ran analyses to establish direct relations between psychiatric symptoms and 376 377 neuroimaging measures of brain structure and function, without immediate reference to pre-defined psychiatric categories. This kind of dimensional, data-driven, 378 approach is particularly relevant in adolescence where there is a good deal of 379 380 evidence suggesting that psychopathology is less differentiated than in adulthood and therefore doesn't fit into the traditional categorical conception of psychiatric 381 disorder^{30,31}. We find two largely non-overlapping sets of brain regions that correlate 382 383 with different sets of psychiatric symptoms. The first symptom dimension predominantly encompassed anxiety/depression symptoms whilst the second 384 385 dimension mainly consisted of executive dysfunction symptoms.

386 The anxiety/depression canonical symptom correlate was significantly associated with T₁, rs-fcMRI and DTI data modalities. Participants scoring highly on this 387 psychiatric scale showed decreased grey matter volume in the middle temporal 388 gyrus, reduced fractional anisotropy in the genu of the corpus callosum, and 389 390 increased functional connectivity between the default mode network and the cerebellum. A recent meta-analysis has demonstrated an association of depression 391 with the right inferior temporal gyrus²², a region exhibiting close connections with the 392 limbic system, consistent with the theory that depression results from dysfunctional 393 cortico-limbic circuits³². The genu of the corpus callosum is a commisural white 394 matter pathway that links left and right prefrontal brain regions³³. Changes in the 395 structure of the corpus callosum are known to result in altered inter-hemispheric 396 connectivity and impaired emotional control³⁴. The genu of the corpus callosum has 397 been shown to be the white matter region with the largest difference in FA between 398

controls and patients with major depression³⁵. The default-mode network is a set of 399 400 brain regions that reliably exhibit a decrease in activity when the brain is engaged in 401 non-self-directed tasks; this network is thought to be primarily responsible for selfinspection and internal monitoring^{36,37}, which are processes overactive in 402 depression³⁸. Increased connectivity between the default-mode network and the 403 cerebellum has been previously reported in drug-naive depressive patients²⁴, 404 405 consistent with its recently discovered involvement in complex cognitive and emotional processes³⁹. 406

407 We found that the executive dysfunction psychiatric symptom group was significantly 408 correlated with neuroimaging measures derived from T₁ data. Here, decreased grey 409 matter was localised to the Right Middle Temporal Gyrus, previously linked to ADHD²⁵. These results are more difficult to interpret as the function of this brain area 410 411 is not well studied. As with the rest of the temporal lobe, this brain area is thought to be responsible for generating meaning from sensory inputs¹⁹. Further, the temporal 412 lobe functions in close relation with the hippocampus in the formation of memories¹⁹. 413 414 Therefore, atrophied grey matter in this brain area may help explain the learning 415 deficits often observed with ADHD-like symptoms.

416 The identification of brain systems from a population-based cohort that is not 417 suffering from any other psychiatric illness has major advantages: By identifying sub-418 clinical correlates of psychiatric illness, prior to the full manifestation of disorder, it is 419 possible to avoid the potential impact of effects indirectly related to illness, such as 420 substance use and medication effects. For example, 17% percent of the 421 schizophrenia, and 21% percent of the Bipolar samples but none of the healthy 422 controls studied here have a history of alcohol abuse, which has been linked to widespread decreases in grey matter⁴⁰. In addition, various psychiatric medicines, 423

including lithium, which is often prescribed to Bipolar patients, have also been linked
to alterations in grey matter volume⁴¹, it is possible that lithium-induced increases in
grey matter volume may have contributed to the observed absence of significant
findings in Bipolar patients in this study.

428 We compared the efficacy of the data-driven msCCA-regression method with 429 pre-defined psychiatric scales of internalising and externalising symptoms. We found 430 that the data driven approach identified relations between symptoms and the brain 431 that were significantly stronger than a similar approach using standard internalising 432 and externalising psychiatric symptom scales, defined without reference to any 433 underlying biology. The fact that the canonical symptom groups show a stronger 434 correlation with neuroimaging measures than pre-defined scales is important as it 435 shows that data driven methods may offer the potential to refine existing psychiatric categorisations⁶. 436

437 It is notable that grey matter correlates of psychopathology are already 438 present at age 14 years, preceding the development of symptoms that only become manifest 5 years later, at 19 years. We also found that the brain correlates 439 440 identified in the adolescent general population replicate in independent clinical 441 samples of corresponding psychiatric disorders, namely depression and ADHD. In 442 addition to validating our primary results gained from population cohorts, these 443 results raise the prospect of using neuroimaging measures, discovered in preclinical 444 samples, as predictors of future psychopathology, thus enabling the development of targeted interventions in a young age group, where such measures are most 445 effective in reducing the burden of mental illness⁴². 446

447 It is important to note that the results of the msCCA-regression analysis 448 applied here, depend on the distribution of prevalence of psychopathological

symptoms in each sample investigated. Thus, while a general population sample may yield an index of the normative variance in psychiatric symptoms from a broader range of different psychiatric disorders and their neural correlates, a patient sample might yield a narrower biological stratification within distinct clinical psychiatric categories, e.g. different biotypes of depression⁵, or symptoms of psychosis.

455 By basing symptom groups upon brain correlates, and by demonstrating specific associations of these correlates with clinical psychopathology, we have 456 457 characterized stratification markers based on shared neural substrates. By 458 discovering that these brain correlates identified in young adults are already 459 established during adolescence, we have characterized biological risk markers prior 460 to the manifestation of symptoms. Our work thus shows how major obstacles can be 461 overcome in developing a taxonomy for psychiatric illness based on quantifiable 462 neurobehavioral phenotypes.

- 463
- 464 465

466

467

468

- 469 470
- 471

472

474

- 475
- 476
- 477
- 478
- 479
- 480 Methods
- 481 Ethics Statement

482 IMAGEN

- Each site sought and received approval from the relevant local research ethics
- committee. Written consent was obtained from each participant and a parent or
- 485 guardian.

486 Munich-Depression

- The studies were approved by the respective local ethics committees: The ethical
- committee of the Ludwig-Maximilians-Universität, Munich, Germany and the ethical
- committee of the Bayerische Landesärztekammer, Munich, Germany. All participants
- 490 provided written informed consent.
- 491 **TOP**
- All participants were recruited between 2003 and 2009 as part of an ongoing study of
- 493 psychotic disorders (Thematically Organized Psychosis study). After complete
- description of the study, all participants gave informed consent to participate. The

study was approved by the Regional Committee for Medical Research Ethics and the
Norwegian Data Inspectorate.

497 **ADHD**

498 This study was approved by the regional ethics committee (Centrale Commissie

499 Mensgebonden Onderzoek: CMO Regio Arnhem – Nijmegen; 2008/163; ABR:

500 NL23894.091.08) and the medical ethical committee of the VU University Medical

501 Center. Informed written consent was obtained from each participant. For children

⁵⁰² under 18, both parents and children gave consent.

503 Study Protocol

504 We developed a method, termed msCCA-regression to find multivariate relationships between psychiatric symptoms, and multiple neuroimaging modalities 505 simultaneously; In this case, voxel-based morphometry (VBM)¹⁸ measures of grey 506 507 matter volume, fractional anisotropy (FA) derived from DTI data, and normalized using tract based spatial statistics (TBSS)¹⁹, and resting state functional connectivity 508 neuroimaging measures⁴³. msCCA-regression analysis was carried out in the 509 510 general population IMAGEN sample, when participants were aged 19. Additional 511 analyses were then applied in order to localize associations between psychiatric 512 symptoms, and neuroimaging measures of brain structure and function. We then 513 analyzed neuroimaging and symptom data at age 14 in order to determine whether 514 this multivariate relationship already existed at this earlier time-point. Following this, 515 we assessed the clinical significance of our findings by conducting case-control 516 comparisons of the structural markers found in the IMAGEN analysis, in several 517 clinical samples. The following text gives a more detailed description of the methods described here. 518

519 **IMAGEN Analysis**

520 IMAGEN is a large-scale neuroimaging-genetics cohort study conducted with the aim 521 of understanding the biological basis of individual variability in psychological and behavioural traits, and their relation to common psychiatric disorders⁴⁴. The study 522 involves a thorough neuropsychological, behavioural, clinical and environmental 523 524 assessment of each participant. Participants also undergo biological 525 characterisation, with the collection of T₁ weighted MRI (sMRI), diffusion tensor 526 imaging (DTI), task-based fMRI (t-fMRI), resting-state fMRI (rs-fcMRI) and genetic 527 data. We used T_1 weighted, DTI, and rs-fcMRI data in the current investigation.

528 Participants

529 The analysis was carried out on participants drawn from the IMAGEN sample (see

⁵³⁰ for further details: Schumann et al⁴⁴. For IMAGEN, a general population sample of

531 Caucasian adolescents were recruited from eight sites across France, Ireland,

532 England and Germany. Data was collected at age 14, 16 and 19 years. After a

533 conservative quality control of MRI acquisitions and DAWBA questionnaires,

participants with complete data were used in the subsequent data analysis. No

statistical analyses were used to pre-define sample size. However, the sample size

used was simlar to that reported in previous studies^{10,12}.

537 **DAWBA**

Psychiatric symptoms of the IMAGEN participants were assessed using screening
 questions from the development and wellbeing assessment (DAWBA), a wide
 ranging psychiatric screening questionnaire⁴⁵. Participants were asked screening

541 questions, assessing symptoms of: specific fears, social fears, stress after a very

542 frightening event, obsessions and compulsions, worrying, depression, rapidly 543 changing mood, attention and activity, troublesome behavior, drug and alcohol use, concern about appearance and strange/frightening experiences; if enough of these 544 545 questions were answered in the affirmative, a more in-depth assessment of symptoms associated with that disorder was made. DAWBA screening questions 546 547 have previously been used to define subthreshold clinical symptoms in neuroimaging studies of subclinical psychopathology⁴⁶. The strength and difficulties questionnaire 548 (SDQ) was also used in the present investigation as this questionnaire contributes to 549 the assignment of diagnostic status in the DAWBA⁴⁵. Questions in the SDQ are 550 551 categorized into broad internalising and externalizing domains. The data of four of 552 the questions asked had a standard deviation of zero amongst the participants 553 asked, and were therefore not used in subsequent analyses. The full set of 554 psychiatric questions asked in the present investigation can be found in 555 Supplementary Table 1, the questionnaire items that were omitted from the analysis 556 are marked here. At the time of the analysis conducted here, DAWBA/SDQ data had 557 been collected for 1510 participants. Of these, data was incomplete for 239 558 participants, and was not used.

559

560 **T₁ Weighted MRI Acquisition**

561 Scanning took place at eight different sites across Europe, using scanners built by

four different manufacturers (Siemens, Philips, General Electric, Bruker). High

resolution, T₁ weighted images were obtained using a Magnetization Prepared Rapid

564 Acquisition Gradient Echo (MPRAGE) sequence, based on the ADNI protocol

565 (http://www.loni.ucla.edu/ADNI/Cores/index.shtml). Scan parameters were

standardized across sites to the highest degree possible (sagittal slice plane;

repetition time: 2.3 s; echo time 2.8 ms; flip angle 8°; 256×256×160 matrix; isotropic
voxel size: 1.1 mm).

569 VBM Pre-processing

570 At the time this investigation was conducted, T_1 data had been acquired for 1400 571 participants. All scans were visually inspected and manually reoriented. 285 scans 572 were discarded from the analysis for either movement artifacts, strong field 573 inhomogeneities, abnormal field of view, abnormally reduced cerebellum and for 574 brace artefacts. The resulting 1,115 scans were used to build the study specific template. Baseline and Follow up two scans were preprocessed using both the 2008 575 576 version of the Voxel Based Morphometry toolbox (VBM8) running in SPM8 (v.5236). 577 Given the young adults recruited in IMAGEN, we first used VBM8 in order to avoid 578 using adult tissue probability maps (TPM) to initiate the segmentation process. The 579 VBM8 toolbox segmentation relies on an adaptive Maximum a Posterior technique 580 and TPMs used in VBM8 are for registration purposes only. Diffeomorphic 581 registration (Dartel) was then used to register the 1,115 images, and to generate the study-specific population average template⁴⁷. We then resliced the data to 582 583 1.5x1.5x1.5mm voxel size. Smoothing was carried out using an isotropic 8 mm full 584 width at half maximum Gaussian smoothing kernel. We created a mask for the 585 sample by taking the mean across all VBM maps included in the sample. We thresholded the mask at >0.4. We used a stringent mask to avoid overfitting the 586 data⁴⁸. We then extracted all voxel values within this mask, resulting in 241,544 grey 587 588 matter voxels.

589 **DTI Acquisition**

Diffusion tensor imaging acquisition sequence based on the study by Jones et al⁴⁹. Diffusion tensor images were acquired using an Echo Planar imaging sequence (b=0 and 32 directions with b-value 1300 s/mm²; axial slice plane; echo time = 104ms; 128x128x60 matrix; voxel size 2.4x2.4x2.4 mm), adapted to tensor measurements (for example, FA, mean diffusivity (MD)) and tractography analysis.

595

596 **TBSS Pre-processing**

597 At the time this study was conducted, DTI data had been acquired for 1412 598 participants. Of these, 71 were not usable due to: signal dropouts or too much 599 rotation. Diffusion imaging data was pre-processed using software from the FSL toolbox (www.fmrib.ox.ac.uk/fsl)⁵⁰. We preprocessed the remaining 1341 scans 600 using tract based spatial statistics (TBSS)¹⁹. Pre-processing was carried out in the 601 602 following manner: An affine registration was applied to the first B₀ image for head 603 motion and eddy current correction. Brain extraction was carried out using BET. 604 Diffusion tensor fitting was then used to obtain fractional anisotropy (FA) maps for 605 each participant. All participants' FA data was aligned into a common space using 606 the non-linear registration tool FNIRT, using a b-spline representation of the 607 registration warp field. The mean was then taken across all FA maps to create an FA 608 averaged image. This map was then 'thinned' to create a mean FA skeleton, which 609 was then thresholded at FA > 0.2, keeping only the major white matter tracts. Each 610 participant's aligned FA data was then projected onto the mean skeleton. We then 611 used these skeletonised maps in all subsequent analyses. The final mask used 612 contained 106,812 voxels. A further 10 scans were not used due to masking or 613 normalization issues in TBSS.

614 **Resting State fMRI Acquisition**

- 615 Resting state fMRI scanning of the IMAGEN participants was carried out at multiple
- sites. The following parameters were standardized: number of volumes (164), TR =
- 2.2s, TE = 30ms, flip angle = 75, number of slices/ddas = 40/3, slice thickness = 2.4
- 618 mm, slice gap = 3.4 mm, voxel size = $3.4 \times 3.4 \times 2.4 \text{ mm}^3$, matrix size = 64^2 , FOV =
- 619 **218 mm**.

620 Resting State fMRI Preprocessing

- At the time of this investigation, we had collected rsfMRI scans for 1067 participants.
- Of these scans, 157 were not used, either because over 5% of scans in that
- participant exhibited artifacts of some kind, or if over 5% of volumes showed a
- 624 fractional displacement of over 0.5mm. Preprocessing of resting-state data was
- 625 performed with routines from FMRIB's Software Library (FSL v5.0.9)⁵⁰ and Advanced
- 626 Normalization Tools (ANTs v1.9.2)⁵¹.
- Motion correction was carried out, applying a rigid body registration of each
 volume to the middle volume (FSL MCFLIRT).
- 2) Non-brain tissue was removed (FSL BET).
- 3) Spatial smoothing was applied using a 5mm FWHM Gaussian kernel.
- 4) Independent component analysis (FSL MELODIC) was run for each data set.
- Artifact components were identified using an automatic classification
- algorithm, and subsequently regressed from the data (ICA-AROMA v0.3) 52,53 .
- 634 ICA-AROMA⁵² has been shown to be as effective as motion parameter
- regression, with additional spike regression and 'scrubbing', in the removal of

636	motion related effects on functional connectivity measures derived from
637	resting state fMRI data. However, this procedure has the additional benefit
638	that it preserves more signal of interest than these methods ^{53.}
639	5) The resulting cleaned data set was de-trended (up to a third degree
640	polynomial).
641	6) Co-registration to a high-resolution T_1 image (FSL FLIRT using the BBR
642	algorithm), and normalization to 2mm isotropic MNI standard space (ANTs)
643	was carried out.
644	7) We used the CompCorr procedure to further clean the data of physiological
645	noise ⁵⁴ . To do this: we created white matter (WM) and cerebrospinal fluid
646	(CSF) masks by taking the mean of the WM and CSF segmentations from the
647	VBM analysis, and thresholding them at 0.95, we then resliced these maps
648	into the same space as the rsfMRI data. We then extracted timecourses from
649	voxels within these regions, and took the first three principal components of
650	this signal for both WM and CSF maps. These six principal component signals
651	should represent non-neuronal signal. We then regressed this non-neuronal
652	signal from voxel timecourses across the rest of the brain.
653	8) Lastly, preprocessed and normalized resting-state data sets were resliced to
654	3mm isotropic voxels.

657 Mapping rs-fMRI data

- We first generated 55 regional nodal timecourses using dual regression on
 nodal regions established in the UK biobank sample¹⁷.
- We mapped the correlation between nodal regions using Pearson's pairwise
 correlation coefficient, for each participant, thus producing a connectivity
 matrix for each participant. This connectivity matrix consists of 1,485
 connections between nodes.
- 664 3) We then transformed these connectivity values using Fisher's Z-score665 transform.

666 Different Neuroimaging Processing Strategies

667 A wide range of different preprocessing strategies can be applied in the analysis of neuroimaging data. Approaches to analysing DTI and T1 can be categorised into two 668 broad types: voxelwise, and atlas based approaches^{18,55}. We chose to analyse this 669 670 data at the voxelwise level, as this allows for the highest level of spatial specificity. 671 Although it is also technically possible to analyse rs-fcMRI data across the whole 672 brain at the voxelwise level, this approach results in an enormous number of 673 features: When mapping connectivity at the voxelwise level, in a dataset made up of 674 N voxels, we are left with $(N^{*}(N-1))/2$ connections between those voxels. In the 675 current investigation, N = 57,053, leading to $N^{*}(N-1)/2 = 1.63$ billion inter-regional 676 connections. This would lead to a huge amount of redundancy in the data and computational, statistical and interpretational issues. For this reason, we mapped the 677 678 connectivity between a pre-defined set of nodes. We used nodal definitions resulting 679 from previous work applying independent component analysis (ICA) to the UK biobank sample¹⁷. We used this nodal definition as it derives from the largest extant 680 sample of neuroimaging data. In order to test whether the results we obtained were 681

682 robust to different nodal definitions, we also mapped inter-regional connectivity using the widely used Power atlas⁵⁶ and achieved similar results (Supplementary Figure 683 6). 684

685 **Canonical Correlation Analysis and Sparse Canonical Correlation Analysis**

Canonical correlation analysis (CCA) is a very general statistical method used to 686 identify linear relationships between two or more sets of variables⁵⁷. It can be

thought of as a generalization of multiple linear regression. The objective of CCA is 688

to identify a relationship between two (or more) sets of variables, where there is no 689

690 distinction between which variables are considered dependent, and which are

691 considered independent. This method identifies weights for each variable, such that

692 the weighted sum of variables in each set is maximally correlated with the weighted

sum of variables from the opposite set, assuming a linear relationship. 693

694 Consider two matrices X_1 and X_2 , where each row denotes one of *n* observations, and each column denotes one of p_1 or p_2 features. CCA seeks to find the weight 695 vectors w_1 and w_2 that maximise the correlation: 696

697 $\rho = corr(X_1 w_1, X_2 w_2).$

687

698 This optimisation problem can be written as:

 $\rho = max_{w_1,w_2} w_1^T X_1^T X_2 w_2$

699 Subject to the constraints:

 $w_1^T X_1^T X_1 w_1 = 1$ and $w_2^T X_2^T X_2 w_2 = 1$. 700

We assume that the columns of X_1 and X_2 have been standardised to have a mean of zero and a standard deviation of one. The vectors X_1w_1 and Xw_2 are referred to as canonical variates.

Classical CCA is extremely powerful, but cannot be applied in situations where there are a more features than samples (i.e., $p_1 > n$ or $p_2 > n$, which is typically the case in neuroimaging studies). Interpreting and describing results from CCA can be difficult because the estimated weights are not sparse. This means that some variables may make negligible but non-zero contributions to the variance explained between sets. Sparse canonical correlation analysis (sCCA) was developed to address these issues^{11,58,59}.

sCCA uses an L₁ penalty on canonical weights, which forces some of them to take a value of exactly zero. Furthermore, sCCA can also be applied in scenarios where there are more features than samples (p > n). The optimization criteria for sCCA can be written in the following manner:

$$\rho = max_{w_1,w_2} w_1^T X_1^T X_2 w_2$$

715 Subject to the constraints:

716 $||w_1||^2 = 1$, $||w_2||^2 = 1$, $||w_1||_1 \le c_1$ and $||w_2||_1 \le c_2$

Here, c_1 and c_2 are assumed to fall within the bounds $1 \le c_1 \le \sqrt{p_1}$ and $1 \le c_2 \le \sqrt{p_2}$,

where p_1 and p_2 are the number of features in views X_1 and X_2 respectively.

719 Multiple Sparse Canonical Correlation Analysis Regression

The formulation of sparse canonical correlation analysis described in the text above

is designed to find relations between two views of a dataset. However, we have

722 collected data from several different neuroimaging modalities, and would like to 723 utilize information from each of them. A somewhat naive approach to finding relations between psychiatric symptoms and multiple neuroimaging measures would 724 725 be to include all available neuroimaging modalities in one view of the canonical 726 relation, with psychiatric symptoms in the other view. However, this approach is likely 727 to be problematic as different modalities are associated with very different numbers 728 of features. For example, the functional connectivity data used in the present 729 investigation has only 0.6% of the number of features that the VBM data has. As 730 such, if these modalities were entered into the same model, the VBM data would 731 overwhelm the functional connectivity data.

732 We developed an approach designed to maximise the cross-correlation between 733 psychiatric symptoms, and multiple neuroimaging modalities simultaneously, we then 734 combined these modalities in a linear regression model. Formulations of canonical 735 correlation analysis that are able to find relations between more than two sets of data 736 are termed multiple or generalised canonical correlation procedures. A widely used optimisation criteria for multiple canonical correlation analysis is to maximise the sum 737 of correlations between each of the different views of a dataset⁶⁰. Witten et al have 738 formulated a sparse version of multiple canonical correlation analysis⁵⁸: this 739 formulation is designed to maximise the sum of correlations between all views of the 740 741 data. However, in the present investigation, we are only interested in finding 742 correlations between neuroimaging measures, and psychiatric questionnaire 743 responses; we do not wish to optimise the correlation between different 744 neuroimaging measures.

As such, we seek to maximise the following relation:

$$max_{\boldsymbol{w}_1,\dots,\boldsymbol{w}_n}\boldsymbol{w}_1^T\boldsymbol{X}_1^T\sum_{i=2}^n\boldsymbol{X}_i\boldsymbol{w}_i$$

746 Subject to the constraints:

747
$$\|w_1\|^2 = 1$$
, $\|w_i\|^2 = 1$, $\|w_1\|_1 \le c_1$ and $\|w_i\|_1 \le c_i$

748 This method simultaneously optimizes the correlation between a weighted sum of 749 variables in the target set, X₁, with a weighted sum of variables in the other sets. In the present investigation, X₁ is a matrix of psychiatric symptoms and X₂ to X_n are 750 751 neuroimaging measures of brain structure and function. Using this method, we are 752 able to maximise the correlation between psychiatric symptoms, and several 753 different neuroimaging modalities within the same integrated model. A natural choice 754 for the statistic of interest, in any inference carried out using this procedure, would be the sum of correlations between the symptom data, and the neuroimaging measures 755 756 of brain structure and function. However, a sum of correlations is of less practical 757 benefit than understanding how much total variance is shared between neuroimaging measures of brain structure and function, and psychiatric symptoms. 758 Therefore, in the final step of this process, we combine canonical neuroimaging 759 760 variables in an ordinary linear regression model. Canonical variables are defined as:

- $C_i = X_i w_i$
- Canonical variables are then combined in the prediction of psychiatric symptomsusing ordinary linear regression:

$$C_1 = \beta_0 + C_2 \beta_2 \dots + C_n \beta_n + \epsilon$$

We used this approach to establish relations between psychiatric symptoms (C₁), and TBSS (C₂), VBM (C₃), and connectivity measures (C₄) derived from rs-fMRI data and β_n are the associated weights estimated using ordinary linear regression (β_0 is the constant estimated in regression).

msCCA-regression was carried out using in-house codes written in MATLAB. This
algorithm requires an initialization value. In the present study, initial weights were
randomly generated. Weight values associated with psychiatric symptoms were
always constrained to be positive to ensure interpretability.

771 This study is designed to be exploratory in nature. Nevertheless, given the very large 772 guantity of data we sought to integrate, it is likely that some simple priors will help to 773 improve the stability of our results, so long as those priors are well supported. There is a great deal of evidence suggesting that psychopathology is associated with 774 775 decreases in both grey matter, and fractional anisotropy, across psychiatric disorders^{61,62}. For this reason, we constrained the canonical weights on VBM volume 776 777 and FA to be negative. This will help to reduce variance in the model and will help 778 increase interpretability of our results. In contrast, there is no clear evidence that 779 psychiatric illness is associated with increases or decreases in connectivity 780 measures derived from BOLD-fMRI. Therefore, we did not add constraints to the 781 functional connectivity data.

782

783 Stability Selection

Although msCCA-regression (and sCCA) have advantages over classical CCA in terms of interpretability, it can suffer from instabilities due to their utilization of an L₁ penalty to introduce sparsity²¹. This is particularly true when p >> n, and when there is a high degree of collinearity in the data. Stability selection is a widely applicable feature selection procedure that can address this problem²¹. This procedure has the added benefit that it makes the results less sensitive to the choice of L₁ penalty.

790 The conceptual underpinning of stability selection is very simple: if a model is 791 repeatedly resampled, features exhibiting a 'real' effect will be selected more often 792 than noise. Using stability selection, data is repeatedly split into random sub-samples 793 of size $n_t/2$ (where n_t is the total number of participants in the training dataset). In this 794 work, resampling was carried out a hundred times. msCCA was applied to each 795 resample, and those features that appear more often are deemed to be more stable. 796 Deciding which variables are stable requires a threshold: π_r is defined as the fraction 797 of samples in which a particular variable must be observed to be considered stable. We set π_r to 0.9, which means that a particular variable must be present in 90% of 798 799 resamples to be considered stable. The outcome of this stability selection procedure 800 is a set of stable features. A benefit of stability selection is that it is insensitive to tuning parameters. Here, we simply set the L₁ penalty at $\sqrt{p}/2$, which is halfway 801 along the regularization path running from 1 to \sqrt{p} . It is worth noting that the stability 802 803 selection procedure is easily parallelizable here as it simply involves re-applying the 804 msCCA-regression algorithm to multiple different resamples of the same data.

805

806 Analysis Design

The L₁ penalty used in sCCA means that the parametric tests used for significance 807 testing in classical CCA (for example Wilk's Lambda)⁶³ cannot be used here, 808 809 necessitating the use of permutation testing to determine whether results are 810 significant. We assessed the in-sample significance of the results we obtained here, 811 then replicated these findings using an out-of-sample, hold-out set design. This kind 812 of experimental design has a number of advantages in the present context: using a 813 training/testing design, it is possible to obtain an unbiased estimate of effect size. We 814 used a hold-out set design in preference to a cross-validation procedure. This is 815 because cross-validation involves the training and testing of multiple statistical 816 models, one for each cross-validation fold, which precludes the use of a single model 817 for further validation/characterization. A related advantage is that it is possible to 818 carry out further characterization of the test set results, due to the fact that we are 819 able to estimate effect size in an unbiased way.

820 In detail, the analysis design was carried out as follows:

1) Psychiatric symptom data, and data from the VBM, TBSS and rs-fcMRI

neuroimaging modalities was extracted and transformed into $n_t \ge p_i$ matrices,

- where n_t is the number of participants included in the training dataset, and p_i
- is the number of features included in each of the views of the data.
- 2) The full dataset was randomly split into training and testing sets. The training
 set was made up of 70% of the data whilst the testing set was made up of the
 remaining 30%.

828	3)	The training data was then randomly split into a hundred further resamples.
829		Each resample was made up of $n_t/2$ participant scans, where n_t is the total
830		number of participants in the training dataset.
831	4)	The first stage of the mSCCA- regression algorithm (see above) was then
832		applied to each resample, with a sparsity constraint of $\sqrt{p_i}/2$ in each view of
833		the data.
834	5)	We then recorded which variables, in each view of the data, are present in
835		over 90% of resamples. These variables are considered to be stable, and are
836		retained.
837	6)	We then re-applied the msCCA algorithm to the data, without sparsity
838		constraints, on the variables than survived more than 90% of resamples.
839	7)	We then combined the neuroimaging canonical variates we found in the
840		previous step in a prediction model on the symptom canonical variate, using
841		ordinary least squares regression. We then recorded the correlation between
842		the neuroimaging prediction model, and the symptom canonical correlate.
843	8)	We then permuted the training data, and repeated steps 3-7. This was done
844		for 10,000 different permutations of the training data labelling. In each case,
845		we recorded the correlation between the neuroimaging model, and the
846		canonical correlate of psychiatric symptoms. In this way, we built up a
847		permutation distribution to assess the significance of the relation between
848		symptom and neuroimaging data in the experimental labelling, within the
849		training dataset.

9) We then applied the trained model to the test set to produce canonical
correlates of symptom and neuroimaging measures. We recorded
associations for both the full model, and between the psychiatric symptom
score, and each of the individual neuroimaging canonical correlates.

10) We then randomly permuted the data rows in the testing set and recalculated correlation values between symptom and brain canonical
correlates. We recorded associations between psychiatric symptoms and the
full neuroimaging model, for each of 10,000 permutations of the experimental
labelling.

859 11) It is also interesting to find the significance of the individual neuroimaging 860 modalities. However, as we are testing the significance of multiple 861 neuroimaging modalities, it is necessary to correct for multiple comparisons across these different modalities. This is easily done using the distribution of 862 863 the maximal statistic: for each permutation of the experimental labelling, we 864 calculate the association between the symptom score and each of the 865 neuroimaging canonical correlates; the largest of these associations is then 866 recorded. This is done for each of the 10,000 permutations of the test 867 labelling, producing a distribution of the maximal statistic. Correlations 868 between symptom and neuroimaging measures in the experimental labelling 869 are then significant at the FWE-corrected level α if they are above the 100*(1- α) percentile of this distribution. 870

This process is illustrated in Supplementary Figure 1.

872

873 **Confounds**

It is important to account for the effects of confounds, which might otherwise lead to
spurious relations between the different data views⁶⁴. Here, we regressed age,
gender, site and intracranial volume from all data views prior to the sCCA analysis<sup>65⁶⁷. For the connectivity measures derived from rsfMRI data, we also regressed the
mean between-volume fractional displacement, and the percent of slices corrupted
by artefacts, from the scans.
</sup>

880 Additional Analyses to Localise Effects

881 We used msCCA-regression to find multivariate relations between psychiatric 882 symptomatology and neuroimaging measures of brain structure and function. In 883 using msCCA-regression, it is possible to make inferences on relations between sets 884 of psychiatric symptoms and neuroimaging measures across the brain, it is not 885 possible to make inferences on individual brain regions/connections or individual 886 questionnaire items. For this reason, we conducted additional analyses to further 887 deconstruct the relationship between psychiatric symptomatology and the brain. This procedure is similar to a redundancy analysis^{68,69}. In particular, we were interested in 888 889 localising which brain regions exhibited an individually significant association with 890 psychiatric symptomatology.

Conducting further tests on the whole dataset would introduce circularity into the analysis. Therefore, additional inference must be carried out on the testing dataset alone. Nevertheless, the training dataset is still likely to contain useful information, which can be used to guide analyses carried out on the testing dataset, thus decreasing the multiple comparison problem, and increasing the likelihood of finding significant effects in the testing dataset. In the present investigation, we looked for

significant localizable effects in the training dataset, we then used these results to
inform analyses carried out on the testing dataset. In this sense, the training dataset
was used as a 'discovery dataset'.

In the case of the TBSS and VBM data, we sought to localize associations between
symptoms and the brain to the cluster-wise level. In the case of the rs-fcMRI data,
we sought to localize changes to individual inter-regional connections. VBM and
TBSS clusters were defined using an 18-connectivity scheme. This means that
voxels must be connected by a face or an edge to be considered a part of the same
cluster.

⁹⁰⁶ This analysis was carried out in the manner described below:

We calculated the grey matter volume and FA in spatially distinct clusters
 identified in the sCCA analysis applied to VBM and TBSS respectively. We
 extracted connectivity values with non-zero canonical weights. This was done
 in both the training and testing datasets.

- We calculated Pearson's correlation coefficient between the mean of each
 spatially distinct cluster/connection, and the sum of symptom score values.
 This was done separately in the training and testing datasets.
- 3) Rows associated with neuroimaging data in the training set were permuted
 and correlations between clusters/connections, and symptom clusters were
 recalculated. The maximal value was recorded. Training data was permuted
 10,000 times; the maximum correlation value across all clusters/connections
 was recorded for each permutation. Clusters/connections exhibiting a
 significant effect in the training dataset were then determined by comparing

920		correlation values to the distribution of the maximal statistic ^{50, 51} . Because
921		model selection was carried out in the training dataset, conducting inference
922		on the training dataset would constitute "double dipping".
923	4)	Clusters/connections exhibiting a significant effect in the training dataset were
924		taken forward for an analysis carried out in the testing set.
925	5)	We calculated correlation values between clusters/connections in the testing
926		dataset, and the symptom score.
927	6)	Testing data was permuted 10,000 times; the maximum correlation value
928		across all clusters/connections was recorded for each permutation.
929		Clusters/connections exhibiting a significant effect in the testing dataset were
930		determined by comparing correlation values to the distribution of the maximal
931		statistic. Cluster/connection correlations in the testing dataset were then
932		compared to correlations in the distribution of the maximal statistic.
933		Cluster/connection correlations in the experimental labelling, which were in
934		the top 5% of the distribution of the maximal statistic, were considered
935		significant at the FWE corrected level.
936	This p	rocess is illustrated in Supplementary Figure 3.

937 **Finding Multiple Modes of Variation**

Using canonical correlation analysis, it is possible to uncover multiple modes of

variation between datasets. After determining the significance of the first canonical

our set of correlate, we remove the effect of the first set of canonical vectors, and repeat the

analysis. Witten et al used Hoteling's deflation to remove the effect of the first vector;

this approach has been criticized by Monteiro et al, who propose the projection

deflation procedure as an alternative^{11,70}; this is the procedure we use in the present
investigation. Correlations between the different canonical relations are given in
Supplementary Table 6.

946 It is possible to ascertain the significance of all canonical relations after the first by 947 comparing the correlations of subsequent associations to the permutation distribution 948 of the first relation: The first canonical relation between sets is by definition the 949 strongest; any subsequent associations between sets will be weaker than the 950 canonical relation that preceded it. A common means of correcting for multiple 951 comparisons is to compare test statistics in the experimental labelling to the maximal 952 statistic across all tests in the permutation distribution; this distribution is usually termed the distribution of the maximal statistic^{71,72}. In the present investigation, we 953 954 can find this distribution by recording the strength of the first canonical relation, for 955 each permutation. Significance values that are corrected for multiple comparisons 956 can then be found by comparing associations of subsequent modes of variation, with this distribution⁷³. 957

958 Hypothesis Driven Analysis

959 A major advantage of the approach described here is that it allows the grouping of 960 psychiatric illnesses to be driven by their biological underpinnings. Nevertheless, it is 961 an open question whether the symptom groups discovered in the data driven 962 analysis we ran here show a stronger relation to neuroimaging measures of brain 963 structure and function than pre-defined symptom groups. For this reason, we tested 964 whether the widely used internalising/externalising organisation of psychiatric illness 965 is able to explain as much variance in psychiatric symptomatology as this purely data driven method. To do this, we used an approach that is as similar as possible to the 966

967 primary data analysis followed in the main part of the investigation, yet still makes 968 use of the internalising/externalising illness structure: we replaced the symptom 969 matrices used in the main part of the investigation with symptom vectors based on 970 previously defined internalising and externalizing symptom sub-scales from the 971 DAWBA; no sparsity was applied to psychiatric symptom sub-scales. Used in this 972 manner, the msCCA-algorithm reduces to something like a sparse partial least squares regression⁷⁴, where the neuroimaging features are predictors and the pre-973 974 defined internalising/externalising vectors are the targets. This method was applied 975 twice, once to predict the internalising symptom dimension, and once to predict the 976 externalising. We term the internalizing and externalising symptom scales as 977 DAWBA-internalising and DAWBA-externalising respectively. We defined symptoms 978 as belonging to broad internalising or externalising categories in the same way as Aebi et al⁷⁵: The DAWBA-internalising scale was created by summing: specific 979 980 fears, social fears, panic attacks, stress after a frightening event, worrying and 981 depression. The DAWBA-externalising scale was created by summing: Attention and 982 activity, behaviours and attitudes that can get people into trouble, and Cigarettes, 983 Alcohol and Drugs sections of the DAWBA. The SDQ is already split into broad internalising and externalising domains⁴⁵. Therefore, internalising and externalising 984 985 SDQ scores were simply added to these scores to create DAWBA-internalising and 986 DAWBA-externalising scores respectively. The sections: rapidly changing mood, 987 dieting and bingeing and strange experiences that are surprisingly common were not 988 used to create scores as these symptoms do not fit neatly into an 989 internalising/externalising dichotomy. All of these guestions can be found in 990 Supplementary Table 1.

991

992 Longitudinal Analysis

993 The msCCA-regression analysis described above was used to find relations between 994 psychiatric symptoms and neuroimaging measures of brain structure at age 19, 995 when participants were young adults. However, the developmental time period 996 immediately preceding this time point is also of potential interest, with the brain going 997 through important maturational processes and participants being at increased risk for the development of psychopathology⁷⁶. Thus, we applied the msCCA-regression 998 999 algorithm between psychiatric symptoms and neuroimaging measures at age 14. 1000 The results of this analysis are show in Supplementary Figure 8. We did not find a 1001 significant relation between psychiatric symptoms and the brain at this age. As rs-1002 fMRI data is only available for a small sub-sample of the full dataset at age 14, we 1003 only used VBM and TBSS data in this analysis.

1004 It is possible that neuroimaging markers of psychiatric illness precede the 1005 development of full-blown psychiatric symptomatology. To determine whether this 1006 was the case in the present investigation, we took the TBSS and VBM regions 1007 identified as being associated with psychopathology at age 19, we then extracted the 1008 appropriate neuroimaging data from these brain regions at age 14, and correlated 1009 the output with symptoms at age 19. In this way, we showed that neuroimaging 1010 measures at age 14 have predictive value for psychopathology at age 19.

For these analyses, we used the same subjects as were included in our analysis at age 19. We also used the same train-test split within this subject group. We subjected this age 14 data to the same QC procedures as the data taken at age 1014 19. Of the n = 666 subjects used in the msCCA-regression analysis carried out at age 19, 72 subjects had data that did not pass QC at age 14. This left n = 594

subjects for age 14 analyses, with n = 412 subjects in the training group and n = 182
in the testing/replication group.

1018 Clinical Analyses

1019 Using mSCCA-regression, we found a set of neuroimaging features that correlate 1020 with a set of questions assessing psychiatric health. At the group level, participants who score more highly on the vector derived from neuroimaging data will suffer a 1021 1022 larger number of psychiatric symptoms (as measured by the DAWBA). It might 1023 therefore be expected that participants with a clinical diagnosis of a psychiatric 1024 disorder would score more highly on this neuroimaging vector than healthy controls. 1025 To discover whether this was the case, we subjected clinical data to exactly the 1026 same pre-processing as the IMAGEN data; we then looked for changes in grey 1027 matter volume in the regions identified in the initial analysis. A (one-sided) two-1028 sample t-test was used to determine whether patients and controls differed 1029 significantly on this one-dimensional measure. We only used grey matter data here 1030 as this data-type showed the strongest relation to psychopathology in the IMAGEN sample. Furthermore, this data-type is widely available and the number of degrees of 1031 1032 freedom in the MRI scan acquisition parameters is low. The case-control tests we used here make the assumption of data normality, although this was not formally 1033 tested here. 1034

We used the same confounds in this analysis as we did on the IMAGEN data, this includes the use of total grey matter as a covariate of no interest. However, it could still be argued that regional changes are only acting as a proxy for total grey matter. In order to determine whether this is the case, we repeated all pertinent analyses,

using total grey matter as a regressor in addition to total intracranial volume. Theresults of these analyses are shown in Supplementary Figure 10.

1041

1042 Depression sample

1043 The Munich sample consisted of patients with first episode and recurrent unipolar 1044 Depression treated as in-patients at the Max Planck Institute of Psychiatry, Munich, 1045 and healthy control participants. The data for 13 of the participants assessed was not 1046 used as it was deemed to be of insufficient quality, this left: N=614; 400 patients, age 1047 48 [SD 13.8] years, 53% women; 214 control participants age 49 [SD 13.3] years, 58% women, for the most part overlapping with imaging genetic and MDD 1048 association studies reported in collaboration with the ENIGMA consortium^{22,77}. Other 1049 1050 than in the two flagship studies, no bipolar patients were included for reasons of clinical homogeneity. MDD diagnoses were based on clinical consensus in addition 1051 to M-CIDI or SCAN interviews, depending on the original study protocols. The 1052 1053 Munich sample comprised images acquired in subsamples of the Munich 1054 Antidepressant Response Signature Study and the Recurrent Unipolar Depression Case-Control study, both performed at the MPIP. We did not use any statistical 1055 1056 analyses to decide on the sample size used here. However, the sample used was 1057 among the largest of any single study investigating alterations in brain structure in depressed participants⁷⁷. 1058

1059 Schizophrenia/Bipolar sample

1060 Participants with schizophrenia and bipolar disorder were recruited from the

- 1061 Thematically Organised Psychosis (TOP) study. This is a collaborative study based
- at the University of Oslo in Norway. The data for 2 participants was not used as it

1063 was considered to be of insufficient quality, this left: 286 Controls (aged 34 [SD 9.5] years, 46% women), 161 Schizophrenics (aged 32 [SD 8.8] years, 35% women) and 1064 1065 189 participants with Bipolar Disorder (aged 34 [SD 11.5] years, 58% women). 1066 Patients were recruited from the psychiatric unit of Oslo University Hospital and were assessed for psychiatric illness with the Structural Clinical Interview for DSM-IV Axis 1067 I disorders (SCID-I). This assessment was either administered by an MD, or a 1068 clinically trained psychologist, and was used to assess the presence of AXIS I 1069 disorders. Before participation, control participants were screened to exclude serious 1070 1071 somatic and psychiatric illness, substance abuse, or MRI-incompatibility. All participants gave written informed consent before participation. Further information 1072 about this sample and the scan protocols used can be found in Rimol, L. M. et al⁷⁸. 1073 1074 We did not use any statistical methods to pre-define the sample size used in this 1075 investigation. Nevertheless, the sample used is among the largest of any investigating structural brain alterations in Schizophrenia⁷⁹ and Bipolar disorder⁴¹ 1076

1077 ADHD sample

Data for the ADHD sample was taken from the NeuroIMAGE project, a clinical cohort 1078 1079 study. The study is made up of individuals tested at two different sites in the Netherlands, The Donders Centre for Cognitive Neuroimaging in Nijmegen, and the 1080 Vrije Universiteit in Amsterdam. The total sample consisted of 184 participants 1081 suffering from ADHD, 103 unaffected siblings, and 128 healthy controls. Further 1082 1083 information on the participants and the protocols used can be found in von Rhein et al⁸⁰. This sample includes a number of very young participants, which is likely to 1084 1085 introduce a large degree of heterogeneity into the analysis. For this reason, we did 1086 not analyse the data from participants under the age of fifteen. This age divide point

1087	was considered to offer a reasonable trade-off between sample homogeneity and
1088	size. The data for 12 of the participants was not used as it was deemed to be of
1089	insufficient quality. Case-control Analyses were made between 74 healthy controls
1090	(aged 18 [SD 2.0] years, 50% women) and 131 ADHD participants (aged 18 [SD 2.3]
1091	years, 27% women). No formal statistical methods were used to determine the size
1092	of this sample. However, this sample is large compared to similar samples
1093	investigating case-control differences in brain structure in patients with ADHD ⁸¹ .
1094	
1095	
1096	
1097	
1098	
1099	Data Availability Statement
1100	IMAGEN data used in this investigation will be made available upon reasonable
1101	request to the corresponding author. All other data is available upon reasonable
1102	request addressed to the appropriate study leads.
1103	
1104	Code Availability Statement
1105	The core code used to run the analyses reported in this study are available as
1106	Supplementary Software. Supporting code can be found at:
1107	https://github.com/alexjamesing/mscca-regression-code.
1100	
1108	
1109	

1111	
1112	
1113	
1114	
1115	
1116	
1117	
1118	
1119	
1120	
1121	
1122	
1123	References
1124	
1125	1. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental
1126	disorders: A review of recent literature. Curr Opin Psychiatry. 2007;20(4):359-364.
1127	2. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and adolescence: A
1128	longitudinal MRI study. Nat Neurosci. 1999;2(10):861-863.
1129	3. Steinberg L. Risk taking in adolescence: New perspectives from brain and behavioral science.
1130	<i>Current directions in psychological science</i> . 2007;16(2):55-59.

- 1131 4. Gogtay N, Giedd JN, Lusk L, et al. Dynamic mapping of human cortical development during
- 1132 childhood through early adulthood. *Proc Natl Acad Sci U S A*. 2004;101(21):8174-8179.
- 1133 5. Drysdale AT, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers define
- neurophysiological subtypes of depression. *Nat Med.* 2016.
- 1135 6. Insel T, Cuthbert B, Garvey M, et al. No title. Research domain criteria (RDoC): toward a new
- 1136 *classification framework for research on mental disorders.* 2010.
- 1137 7. Lahey BB, Applegate B, Hakes JK, Zald DH, Hariri AR, Rathouz PJ. Is there a general factor of
- 1138 prevalent psychopathology during adulthood? *J Abnorm Psychol*. 2012;121(4):971.
- 1139 8. Zhang X, Mormino EC, Sun N, et al. Bayesian model reveals latent atrophy factors with dissociable
- 1140 cognitive trajectories in alzheimer's disease. *Proc Natl Acad Sci U S A*. 2016;113(42):E6544.
- 1141 9. Rosenberg MD, Finn ES, Scheinost D, et al. A neuromarker of sustained attention from whole-
- 1142 brain functional connectivity. *Nat Neurosci*. 2016;19(1):165.
- 1143 10. Smith SM, Nichols TE, Vidaurre D, et al. A positive-negative mode of population covariation links
- brain connectivity, demographics and behavior. *Nat Neurosci*. 2015;18(11):1565-1567.
- 1145 11. Witten DM, Tibshirani R, Hastie T. A penalized matrix decomposition, with applications to sparse
- 1146 principal components and canonical correlation analysis. *Biostatistics*. 2009;10(3):515-534.
- 1147 12. Xia CH, Ma Z, Ciric R, et al. Linked dimensions of psychopathology and connectivity in functional
- 1148 brain networks. *Nature communications*. 2018;9(1):3003.
- 1149 14. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The development and well-being
- assessment: Description and initial validation of an integrated assessment of child and adolescent
- 1151 psychopathology. Journal of child psychology and psychiatry. 2000;41(05):645-655.
- 1152 15. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage*. 2007;38(1):95-113.
- 1153 16. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: Voxelwise analysis
- of multi-subject diffusion data. *Neuroimage*. 2006;31(4):1487-1505.

- 1155 17. Miller KL, Alfaro-Almagro F, Bangerter NK, et al. Multimodal population brain imaging in the UK
- 1156 biobank prospective epidemiological study. *Nat Neurosci*. 2016;19(11):1523.
- 1157 18. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. *Neuroimage*. 2000;11(6):805-
- 1158 821.
- 1159 19. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: Voxelwise analysis
- of multi-subject diffusion data. *Neuroimage*. 2006;31(4):1487-1505.
- 1161 20. Power JD, Fair DA, Schlaggar BL, Petersen SE. The development of human functional brain
- 1162 networks. Neuron. 2010;67(5):735-748.
- 1163 21. Meinshausen N, Bühlmann P. Stability selection. Journal of the Royal Statistical Society: Series B
- 1164 *(Statistical Methodology)*. 2010;72(4):417-473.
- 1165 22. Schmaal L, Hibar DP, Sämann PG, et al. Cortical abnormalities in adults and adolescents with
- 1166 major depression based on brain scans from 20 cohorts worldwide in the ENIGMA major depressive
- 1167 disorder working group. *Mol Psychiatry*. 2016.
- 1168 23. Chen G, Hu X, Li L, et al. Disorganization of white matter architecture in major depressive
- disorder: A meta-analysis of diffusion tensor imaging with tract-based spatial statistics. Scientific
- 1170 *reports*. 2016;6:21825.
- 1171 24. Guo W, Liu F, Liu J, et al. Increased cerebellar-default-mode-network connectivity in drug-naive
- 1172 major depressive disorder at rest. *Medicine*. 2015;94(9).
- 1173 25. Carmona S, Vilarroya O, Bielsa A, et al. Global and regional gray matter reductions in ADHD: A
- 1174 voxel-based morphometric study. *Neurosci Lett*. 2005;389(2):88-93.
- 1175 26. Krueger RF, Caspi A, Moffitt TE, Silva PA. The structure and stability of common mental disorders
- 1176 (DSM-III-R): A longitudinal-epidemiological study. J Abnorm Psychol. 1998;107(2):216.
- 1177 27. Diedenhofen B, Musch J. Cocor: A comprehensive solution for the statistical comparison of
- 1178 correlations. *PloS one*. 2015;10(4):e0121945.

- 1179 28. Dunn OJ, Clark V. Correlation coefficients measured on the same individuals. Journal of the
- 1180 *American Statistical Association*. 1969;64(325):366-377.
- 1181 29. Whelan R, Watts R, Orr CA, et al. Neuropsychosocial profiles of current and future adolescent
- 1182 alcohol misusers. *Nature*. 2014;512(7513):185-189.
- 1183 30. Lahey BB, Van Hulle CA, Singh AL, Waldman ID, Rathouz PJ. Higher-order genetic and
- 1184 environmental structure of prevalent forms of child and adolescent psychopathology. Arch Gen
- 1185 *Psychiatry*. 2011;68(2):181-189.
- 1186 31. Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions
- of mental disorders in the world health organization's world mental health survey initiative. *World*
- 1188 *Psychiatry*. 2007;6(3):168-176.
- 1189 32. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: Towards
- 1190 development of brain-based algorithms for diagnosis and optimised treatment. *Br Med Bull*.
- 1191 2003;65(1):193-207.
- 1192 33. Witelson SF. Hand and sex differences in the isthmus and genu of the human corpus callosum: A
- 1193 postmortem morphological study. *Brain*. 1989;112(3):799-835.
- 1194 34. Tham MW, San Woon P, Sum MY, Lee T, Sim K. White matter abnormalities in major depression:
- 1195 Evidence from post-mortem, neuroimaging and genetic studies. J Affect Disord. 2011;132(1-2):26-36.
- 1196 35. Chen G, Hu X, Li L, et al. Disorganization of white matter architecture in major depressive
- 1197 disorder: A meta-analysis of diffusion tensor imaging with tract-based spatial statistics. Scientific
- 1198 *reports*. 2016;6:21825.
- 1199 36. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of
- 1200 brain function. *Proceedings of the National Academy of Sciences*. 2001;98(2):676-682.
- 1201 37. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network. Ann NY Acad Sci.

1202 2008;1124(1):1-38.

- 1203 38. Ray RD, Ochsner KN, Cooper JC, Robertson ER, Gabrieli JD, Gross JJ. Individual differences in trait
- 1204 rumination and the neural systems supporting cognitive reappraisal. Cognitive, Affective, &
- 1205 Behavioral Neuroscience. 2005;5(2):156-168.
- 1206 39. Stoodley CJ. The cerebellum and cognition: Evidence from functional imaging studies. *The*
- 1207 *Cerebellum*. 2012;11(2):352-365.
- 1208 40. Guggenmos M, Schmack K, Sekutowicz M, et al. Quantitative neurobiological evidence for
- accelerated brain aging in alcohol dependence. *Translational psychiatry*. 2017;7(12):1279.
- 1210 41. Hibar DP, Westlye LT, Doan NT, et al. Cortical abnormalities in bipolar disorder: An MRI analysis
- 1211 of 6503 individuals from the ENIGMA bipolar disorder working group. *Mol Psychiatry*. 2017.
- 1212 42. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: A
- 1213 heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J
- 1214 *Psychiatry*. 2006;40(8):616-622.
- 1215 43. Biswal B, Zerrin Yetkin F, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of
- resting human brain using echo-planar MRI. *Magnetic resonance in medicine*. 1995;34(4):537-541.
- 1217 44. Schumann G, Loth E, Banaschewski T, et al. The IMAGEN study: Reinforcement-related behaviour
- in normal brain function and psychopathology. *Mol Psychiatry*. 2010;15(12):1128-1139.
- 1219 45. Goodman R. The strengths and difficulties questionnaire: A research note. Journal of child
- 1220 *psychology and psychiatry*. 1997;38(5):581-586.
- 1221 46. Vulser H, Lemaitre H, Artiges E, et al. Subthreshold depression and regional brain volumes in
- 1222 young community adolescents. Journal of the American Academy of Child & Adolescent Psychiatry.
- 1223 2015;54(10):832-840.
- 1224 47. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage*. 2005;26(3):839-851.

- 48. Grellmann C, Bitzer S, Neumann J, et al. Comparison of variants of canonical correlation analysis
 and partial least squares for combined analysis of MRI and genetic data. *Neuroimage*. 2015;107:289310.
- 1228 49. Jones DK, Williams SCR, Gasston D, Horsfield MA, Simmons A, Howard R. Isotropic resolution
- 1229 diffusion tensor imaging with whole brain acquisition in a clinically acceptable time. Hum Brain
- 1230 *Mapp*. 2002;15(4):216-230.
- 50. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image
 analysis and implementation as FSL. *Neuroimage*. 2004;23:S219.
- 1233 51. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs
- similarity metric performance in brain image registration. *Neuroimage*. 2011;54(3):2033-2044.
- 1235 52. Pruim RH, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust ICA-
- based strategy for removing motion artifacts from fMRI data. *Neuroimage*. 2015;112:267-277.
- 1237 53. Pruim RH, Mennes M, Buitelaar JK, Beckmann CF. Evaluation of ICA-AROMA and alternative
- 1238 strategies for motion artifact removal in resting state fMRI. *Neuroimage*. 2015;112:278-287.
- 1239 54. Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for
- 1240 BOLD and perfusion based fMRI. *Neuroimage*. 2007;37(1):90-101.
- 1241 55. Fischl B. FreeSurfer. *Neuroimage*. 2012;62(2):774-781.
- 1242 56. Power JD, Cohen AL, Nelson SM, et al. Functional network organization of the human brain.
- 1243 Neuron. 2011;72(4):665-678.
- 1244 57. Hotelling H. Relations between two sets of variates. *Biometrika*. 1936:321-377.
- 1245 58. Witten DM, Tibshirani RJ. Extensions of sparse canonical correlation analysis with applications to
- 1246 genomic data. *Statistical applications in genetics and molecular biology*. 2009;8(1):1-27.
- 1247 59. Parkhomenko E, Tritchler D, Beyene J. Sparse canonical correlation analysis with application to
- 1248 genomic data integration. *Statistical Applications in Genetics and Molecular Biology*. 2009;8(1):1-34.

- 1249 60. Gifi A. Nonlinear multivariate analysis. John Wiley & Sons Incorporated; 1990.
- 1250 61. Jenkins LM, Barba A, Campbell M, et al. Shared white matter alterations across emotional
- disorders: A voxel-based meta-analysis of fractional anisotropy. *NeuroImage: Clinical*. 2016;12:1022-
- 1252 1034.
- 1253 62. Goodkind M, Eickhoff SB, Oathes DJ, et al. Identification of a common neurobiological substrate
- 1254 for mental illness. JAMA psychiatry. 2015;72(4):305-315.
- 1255 63. Everitt BS, Dunn G. Applied multivariate data analysis. Vol 2. Arnold London; 2001.
- 1256 64. Timm NH, Carlson JE. Part and bipartial canonical correlation analysis. *Psychometrika*.
- 1257 1976;41(2):159-176.
- 1258 65. O'Brien LM, Ziegler DA, Deutsch CK, Frazier JA, Herbert MR, Locascio JJ. Statistical adjustments
- 1259 for brain size in volumetric neuroimaging studies: Some practical implications in methods. *Psychiatry*
- 1260 *Research: Neuroimaging.* 2011;193(2):113-122.
- 1261 66. Pell GS, Briellmann RS, Chan CHP, Pardoe H, Abbott DF, Jackson GD. Selection of the control
- 1262 group for VBM analysis: Influence of covariates, matching and sample size. *Neuroimage*.
- 1263 2008;41(4):1324-1335.
- 1264 67. Voevodskaya O, Simmons A, Nordenskjöld R, et al. The effects of intracranial volume adjustment
- 1265 approaches on multiple regional MRI volumes in healthy aging and alzheimer's disease. Frontiers in
- 1266 *aging neuroscience*. 2014;6.
- 1267 68. Van Den Wollenberg, Arnold L. Redundancy analysis an alternative for canonical correlation
- 1268 analysis. *Psychometrika*. 1977;42(2):207-219.
- 1269 69. Stewart D, Love W. A general canonical correlation index. *Psychol Bull*. 1968;70(3):160-163.
- 1270 70. Monteiro JM, Rao A, Shawe-Taylor J, Mourão-Miranda J, Alzheimer's Disease Initiative. A
- 1271 multiple hold-out framework for sparse partial least squares. J Neurosci Methods. 2016;271:182-194.

- 1272 71. Holmes AP, Blair RC, Watson G, Ford I. Nonparametric analysis of statistic images from functional
- 1273 mapping experiments. *Journal of Cerebral Blood Flow & Metabolism*. 1996;16(1):7-22.
- 1274 72. Westfall PH, Troendle JF. Multiple testing with minimal assumptions. *Biometrical Journal*.
- 1275 2008;50(5):745-755.
- 1276 73. Westfall PH, Young SS. Resampling-based multiple testing: Examples and methods for p-value
- 1277 adjustment. Vol 279. John Wiley & Sons; 1993.
- 1278 74. Friedman J, Hastie T, Tibshirani R. *The elements of statistical learning*. Vol 1. Springer series in
 1279 statistics New York; 2001.
- 1280 75. Aebi M, Kuhn C, Metzke CW, Stringaris A, Goodman R, Steinhausen H. The use of the
- 1281 development and well-being assessment (DAWBA) in clinical practice: A randomized trial. Eur Child
- 1282 Adolesc Psychiatry. 2012;21(10):559-567.
- 1283 76. Steinberg L. Cognitive and affective development in adolescence. *Trends Cogn Sci (Regul Ed)*.
 1284 2005;9(2):69-74.
- 1285 77. Schmaal L, Veltman DJ, van Erp TG, et al. Subcortical brain alterations in major depressive
- 1286 disorder: Findings from the ENIGMA major depressive disorder working group. *Mol Psychiatry*.
- 1287 2016;21(6):806.
- 1288 78. Rimol LM, Nesvåg R, Hagler DJ, et al. Cortical volume, surface area, and thickness in
- schizophrenia and bipolar disorder. *Biol Psychiatry*. 2012;71(6):552-560.
- 1290 79. van Erp TG, Hibar DP, Rasmussen JM, et al. Subcortical brain volume abnormalities in 2028
- 1291 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol
- 1292 *Psychiatry*. 2016;21(4):547.
- 1293 80. von Rhein D, Mennes M, van Ewijk H, et al. The NeuroIMAGE study: A prospective phenotypic,
- 1294 cognitive, genetic and MRI study in children with attention-deficit/hyperactivity disorder. design and
- descriptives. *Eur Child Adolesc Psychiatry*. 2015;24(3):265-281.

1296 81. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in participants with

1297 attention deficit hyperactivity disorder in children and adults: A cross-sectional mega-analysis. The

1298 Lancet Psychiatry. 2017;4(4):310-319.

1299

- 1300
- 1301
- 1302
- 1303
- 1304
- 1305
- 1306
- 1307
- 1308
- 1309
- ____
- 1310
- 1311

1312 Acknowledgments

1313 This work received support from the following sources: the European Union-funded FP6 Integrated 1314 Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) 1315 (LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant 'STRATIFY' (Brain network 1316 based stratification of reinforcement-related disorders) (695313), ERANID (Understanding the 1317 Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways) (PR-ST-0416-1318 10004), BRIDGET (JPND: BRain Imaging, cognition Dementia and next generation GEnomics) 1319 (MR/N027558/1), Human Brain Project (HBP SGA 2, 785907), the FP7 project MATRICS (603016), the 1320 Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and 1321 Addictions) (MR/N000390/1), the National Institute for Health Research (NIHR) Biomedical Research 1322 Centre at South London and Maudsley NHS Foundation Trust and King's College London, the 1323 Bundesministeriumfür Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz 1324 AERIAL 01EE1406A, 01EE1406B, 01ZX1314G, 01GS08147), the Deutsche Forschungsgemeinschaft 1325 (DFG grants SM 80/7-2, SFB 940/2), the Medical Research Foundation and Medical Research Council 1326 (grants MR/R00465X/1 and MR/S020306/1), the National Institutes of Health (NIH) funded ENIGMA 1327 (grants 5U54EB020403-05 and 1R56AG058854-01). Further support was provided by grants from: 1328 ANR (project AF12-NEUR0008-01 - WM2NA, and ANR-12-SAMA-0004), the Fondation de France, the 1329 Fondation pour la Recherche Médicale, the Mission Interministérielle de Lutte-contre-les-Drogues-1330 et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris and INSERM 1331 (interface grant), Paris Sud University IDEX 2012; the National Institutes of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental Health during 1332 1333 Adolescence; RO1 MH085772-01A1), and by NIH Consortium grant U54 EB020403, supported by a

1334 cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. AFM gratefully

acknowledges funding from the Netherlands Organisation for Scientific Research via the

1336 Vernieuwingsimpuls VIDI programme (grant number 016.156.415). The funders had no role in study

1337 design, data collection and analysis, decision to publish, or preparation of the manuscript

1338

1339

1340 Author Contributions

1341 Author Contributions

Pre-processed data: AI, CC, IMV, PGS, HL, TJ, GR; Analysed the data: AI, PGS; Wrote the manuscript:
AI, GS, FB, PGS; Conceptualised the study: AI, GS, TWR, AM, JA, EB; Collected Data: NT, EBQ, TW,
SD, TB, ALWB, UB, CB, PC, TF, HF, VF, HG, PS, PG, YG, AH, BI, VK, JLM, AML, SB, FN, BVN, DPO, MLPM,
SM, JP, LP, MS, AS, MNS, HW, RW, OAA, IA, EDB, JB; Prepared Figures: AI, NT Revised Manuscript:
All Authors

1347

1348 Competing Interests

1349 Dr. Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim 1350 Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee 1351 by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire 1352 & Viforpharma. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford 1353 University Press. The present work is unrelated to the above grants and relationships. Dr. 1354 Barker has received honoraria from General Electric Healthcare for teaching on scanner 1355 programming courses and acts as a consultant for IXICO. Dr. Andreassen received speaker's 1356 honorarium from Lundbeck. Gabriel Robert received financial support from scientific 1357 meetings (Janssen & Janssen, Otsuka-Lundbeck). Dr. Meyer-Lindenberg has received consultant fees from Boehringer Ingelheim, Brainsway, Elsevier, Lundbeck Int. Neuroscience 1358 1359 Foundation and Science Advances. The other authors report no biomedical financial

1360 interests or potential conflicts of interest.

Figure 1: Results of the first msCCA-regression analysis showing relations between 1361 1362 anxiety/depression psychiatric symptoms and neuroimaging measures in the IMAGEN sample. (a): 1363 The full msCCA-regression model linking psychiatric symptoms to VBM, TBSS and rs-fcMRI neuroimaging measures at age 19. We found associations between psychiatric symptoms and 1364 1365 neuroimaging measures of r = 0.59(465) (p = < 0.001) in the training set, and associations between 1366 symptoms and the brain of r=0.23(197), p<0.001, 95% CIs=0.13, ∞ in the test set; (b): Shows the 1367 msCCA-regression model linking psychiatric symptoms with the different neuroimaging measures (c): 1368 Psychiatric symptoms contributing to this relation are shown on the left, their canonical weights are 1369 shown in red. (d): rs-fcMRI measures of functional connectivity. (e): VBM measures of grey matter 1370 volume associated with symptoms. (f): TBSS measures of fractional anisotropy (FA).

1371

1372 Figure 2: Results of the second msCCA-regression analyses showing relations between executive 1373 dysfunction symptoms and neuroimaging measures in the IMAGEN sample, following the removal of 1374 the first canonical relation. (a): The full msCCA-regression model linking psychiatric symptoms to 1375 VBM, TBSS and rs-fcMRI neuroimaging measures at age 19. We found associations between 1376 executive dysfunction symptoms and neuroimaging measures of r = 0.46 (p = 0.004) in the training set, and associations between symptoms and the brain of r = 0.19(197), p = 0.002, 95% CIs = 0.087, 1377 ∞ in the test set; (b) msCCA-regression model linking psychiatric symptoms with the different 1378 neuroimaging measures (c) Symptoms contributing to this relation are shown on the left their 1379 1380 canonical weights are shown in red. (d) rs-fcMRI measures of functional connectivity. (e) VBM

1381 measures of grey matter volume associated with symptoms. (f): TBSS measures of fractional 1382 anisotropy (FA).

1383


1384 Figure 3: Longitudinal analysis of canonical correlates. (a) anxiety/depression symptom correlates: 1385 VBM and TBSS brain correlates established at age 19 are associated with anxiety/depression 1386 behavioural symptoms at age 19 (r =0.19(180), p = 0.003, 95% CIs=0.069, ∞), but not at age 14 1387 (r=0.020(180), p=0.40, 95% CIs=-0.10, ∞). Brain correlates at 14 years predict the manifestation of 1388 behavioral symptoms at 19 years (r=0.14(180), p=0.023, 95% CIs=0.022, ∞). (b) Executive 1389 dysfunction symptom correlates: VBM and TBSS correlates established at age 19 are associated with 1390 behavioral symptoms at age 19 (r =0.15(180), p = 0.024, 95% $CIs=0.028,\infty$), but not at age 14 1391 $(r=0.030(180), p=0.41, 95\% Cls=-0.093, \infty)$. Brain correlates at 14 years do not predict the 1392 manifestation of behavioral symptoms at 19 years (r=0.11(180), p=0.065, 95% CIs =-0.010, ∞).


1393


1394

1395 Figure 4: Differences in the grey matter correlates of anxiety/depression and executive dysfunction 1396 psychiatric symptoms, between cases and controls for a range of psychiatric illnesses. For the box 1397 and whisker plots, the central mark in each box represents the median, with the top and bottom edges 1398 of the box indicating the 25th and 75th percentiles of the sample respectively, whiskers represent 1.5x 1399 the interguartile range and the hollow circles represent sample outliers. For display purposes, total 1400 grey matter in each case-control comparison is divided by the pooled standard deviation. The effect 1401 sizes (calculated using Cohen's D) relating to these differences are shown in the right-hand panel. (a): 1402 Differences in grey matter volume between patients and controls in the anxiety/depression set of grey 1403 matter correlates are shown in the left-hand panel. Clinical psychiatric disorders exhibited the 1404 following case-control differences: Depression: t-statistic=4.61(612), p<0.001, Cohen's D = 0.39, 95% 1405 Cls=0.25, »; Schizophrenia: t-statistic=2.54(445), p=0.002, Cohen's D=0.25, 95% Cls = 0.087, »; 1406 ADHD (t-statistic=1.84(203), p=0.034, Cohen's D=0.26, 95% CIs=0.030, ••; Bipolar: (t-statistic=-1407 0.23(473), p=0.59, Cohen's D=-0.02, 95% CIs=-0.17, ∞). (b): Differences in grey matter volume between patients and controls in the executive dysfunction set of grey matter correlates. Clinical 1408 psychiatric disorders exhibited the following case-control differences: Depression: t-statistic=1.65(612), p=0.050, Cohen's D=0.14, 95% CIs=0.001, ∞ , Schizophrenia: t-1409 1410 statistic=2.81(445), p=0.0026, Cohen's D=0.28, 95% CIs=0.11, ..., ADHD: t-statistic=2.19(203), 1411 p=0.014, Cohen's D=0.32, 95% CIs=0.070, ∞; Bipolar: t-statistic=-1.33(473), p=0.90, Cohen's D=-1412 1413 0.12, 95% CIs=-0.27, ∞.

1414 1415







a.

b.

